Suppr超能文献

公认的5-羟色胺2受体拮抗剂在猪脉络丛中对5-羟色胺1C受体的竞争性拮抗作用。

Competitive antagonism by recognized 5-HT2 receptor antagonists at 5-HT1C receptors in pig choroid plexus.

作者信息

Sahin-Erdemli I, Schoeffter P, Hoyer D

机构信息

Department of Pharmacology, School of Pharmacy, Hacettepe University, Ankara, Turkey.

出版信息

Naunyn Schmiedebergs Arch Pharmacol. 1991 Aug;344(2):137-42. doi: 10.1007/BF00167210.

Abstract

The effects of several antagonists, known to interact with 5-HT2 receptors (ritanserin, LY 53857, ICI 169,369, methysergide, mesulergine and ketanserin), were tested against 5-HT-stimulated production of inositol phosphate in pig choroid plexus, a 5-HT1C receptor model. These antagonists produced dextral shifts of the concentration response curve to 5-HT in a parallel manner, without depressing significantly the maximal response. The following pA2 values (in parentheses) were obtained: mesulergine (8.88), methysergide (8.85), LY 53857 (8.69), ritanserin (8.69), ICI 169,369 (7.86), and ketanserin (6.57). These pA2 values were in good agreement with the pKD values determined in radioligand binding studies performed in pig choroid plexus with [3H]mesulergine. The present data demonstrate that several drugs described as 5-HT2 receptor selective antagonists (e.g. ritanserin, LY 53857 and ICI 169,369) are also potent, competitive and surmountable antagonists at 5-HT1C receptors. Thus, the results provide further evidence for the pharmacological similarity of 5-HT1C and 5-HT2 receptors. However, in contrast to the situation described with methysergide, ritanserin and LY 53857 in several 5-HT2 receptor models, none of these antagonists acted in a non-competitive or unsurmountable fashion at 5-HT1C receptors. These results suggest, but do not firmly rule out, that at least in the presence of the drugs tested in the present study, 5-HT1C receptors in the choroid plexus do not undergo an allosteric modulation; these findings are apparently in contrast to a model proposed previously for 5-HT2 receptors (Kaumann and Frenken 1985, Naunyn-Schmiedeberg's Arch Pharmacol 328:295-300).

摘要

已知几种与5-羟色胺2(5-HT2)受体相互作用的拮抗剂(利坦色林、LY 53857、ICI 169,369、甲基麦角新碱、美舒麦角和酮色林),在5-HT刺激猪脉络丛(一种5-HT1C受体模型)产生肌醇磷酸的实验中接受了测试。这些拮抗剂使5-HT浓度-反应曲线平行地向右偏移,而未显著降低最大反应。获得了以下pA2值(括号内):美舒麦角(8.88)、甲基麦角新碱(8.85)、LY 53857(8.69)、利坦色林(8.69)、ICI 169,369(7.86)和酮色林(6.57)。这些pA2值与用[3H]美舒麦角在猪脉络丛进行的放射性配体结合研究中测定的pKD值高度一致。目前的数据表明,几种被描述为5-HT2受体选择性拮抗剂的药物(如利坦色林、LY 53857和ICI 169,369)也是5-HT1C受体的强效、竞争性和可克服的拮抗剂。因此,这些结果为5-HT1C和5-HT2受体的药理学相似性提供了进一步的证据。然而,与在几种5-HT2受体模型中甲基麦角新碱、利坦色林和LY 共同特征。然而,与在几种5-HT2受体模型中甲基麦角新碱、利坦色林和LY 53857的情况相反,这些拮抗剂在5-HT1C受体上均未表现出非竞争性或不可克服的作用方式。这些结果表明,但不能完全排除,至少在本研究中测试的药物存在的情况下,脉络丛中的5-HT1C受体不会发生变构调节;这些发现显然与先前为5-HT2受体提出的模型(考曼和弗伦肯,1985年,《瑙恩-施米德贝格药理学文献》328:295 - 300)相反。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验